Visterra gets $30M for flu drug as Sarepta, Alere also advance treatments

With annual flu season looming, a Cambridge biotech firm is getting a $30 million shot in the arm to develop its drug which could not only cure the disease, but prevent it...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.